Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

Witzens-Harig, Mathias; Reiz, Monika; Heiß, Christian; Benner, Axel; Hensel, Manfred; Neben, Kai; Dreger, Peter; Kraemer, Alwin; Ho, Anthony D.

doi:10.1007/s00277-008-0560-2

Cited by 23 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Witzens-Harig et al studied a subset of 91 patients included in a prospective randomized trial of rituximab therapy (eight cycles of 375 mg/m 2 rituximab every 3 months) versus observation in patients with CD20 + B-cell NHL [41]. Their objective was to find evidence of QoL impairment in patients under rituximab maintenance therapy.…”

Section: Maintenance Regimenmentioning

confidence: 98%

Quality of life following treatment for B-cell lymphoma

Martis

Gisselbrecht

Mounier

2011

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Clinical outcome for B-cell non-Hodgkin's lymphoma has been greatly improved through the combination of new treatment options, in particular noncytotoxic drugs that specifically target disease mechanisms. Furthermore, in many cases, lymphoma survivors have to cope with long-term toxicity. Therefore, as with survival and remission length, the assessment of quality of life (QoL) is a major consideration when judging therapeutic benefit in patients. The aim of this article is to discuss the impact of widespread treatments on QoL and the relevance of QoL assessment in B-cell non-Hodgkin's lymphoma in day-to-day clinical practice. Additional studies of QoL in the general population, the associations between QoL and treatment strategy, QoL and specific situations (i.e., stem-cell transplantation and aging population) are also considered.

show abstract

Section: Maintenance Regimenmentioning

confidence: 98%

Quality of life following treatment for B-cell lymphoma

Martis

Gisselbrecht

Mounier

2011

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…With a total of 91 patients eligible for evaluation, no significant differences between groups could be detected, indicating that rituximab maintenance does not affect the quality of life. 45 …”

Section: Safety Tolerability and Quality Of Lifementioning

confidence: 99%

Expanded use of rituximab in the management of non-Hodgkin lymphoma

Eichenauer

Engert²,

Schulz³

2009

OTT

View full text Add to dashboard Cite

Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemented by rituximab (R-chemotherapy) was shown to be more effective than chemotherapy alone. This holds true for indolent as well as aggressive NHL. Rituximab was also shown to be beneficial when used as maintenance therapy or part of salvage and re-induction regimens in relapsed NHL. Administration of rituximab is generally well tolerated. The most common side effects including fever, urticaria and bronchospasm are mostly mild, treatable and restricted to the infusion period. Thus, rituximab can usually be administered in an outpatient setting. Due to its favorable effect/side effect ratio, clinical trials are currently evaluating a possible role for rituximab in several other diseases such as Hodgkin lymphoma (HL) and non-malignant autoimmune disorders. This review aims at giving an overview of the pharmacological properties of rituximab and summarizing key publications and recent literature on its use in NHL.

show abstract

“…QOL was evaluated during a prospective randomized trial of rituximab maintenance therapy in 91 NHL patients (38 with DLBCL and 16 with FL). 53 QOL was assessed with the standardized questionnaires EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS). No differences in QOL were found between the groups that received rituximab maintenance or standard observation.…”

Section: Patient Focused Outcomesmentioning

confidence: 99%

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Badin

Hayslip

2010

CEOR

View full text Add to dashboard Cite

Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon treatment efficacy, quality of life, and safety of rituximab or rituximab-containing regimens. More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma’s impacts on patient’s productivity and their caregivers. We conclude that adding rituximab to standard chemotherapy treatment for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings during both induction and maintenance therapies. Despite extensive review of the literature, many important questions have yet to be answered in the rituximab era and these represent important directions for future study.

show abstract

Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

Cited by 23 publications

References 17 publications

Quality of life following treatment for B-cell lymphoma

Quality of life following treatment for B-cell lymphoma

Expanded use of rituximab in the management of non-Hodgkin lymphoma

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Contact Info

Product

Resources

About